Aethlon Medical (AEMD) CEO Note: Nasdaq listing, equity financing and therapeutic pipeline expansion

SAN DIEGO, Aug. 6, 2015, AEMD, NASDAQ, /PRNewswire/ Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. On July 24th, members of our management team and board of directors joined me to ring the closing bell at the Nasdaq Stock Market. The ceremony, which celebrated our recent Nasdaq listing, followed the completion of a $6 million equity financing and marks a new era for our organization. Beyond enhancing our balance sheet, the financing provides the capital resources necessary to support an FDA-approved study that we previously initiated to advance our Hemopurifier® as a candidate to treat a broad-spectrum of viral pathogens. By listing on Nasdaq, we broadened our access to the capital markets, which in turn establishes a realistic backdrop for us to expand our therapeutic pipeline to include clinical opportunities that exist for Hemopurifier® therapy in cancer care. In this regard, we are taking decisive steps to adv


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: